Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zai Lab Limited
< Previous
1
2
Next >
Zai Lab Announces Participation in Investor Conference in January 2025
December 12, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
November 27, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
November 18, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
November 14, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Proposed Public Offering of American Depositary Shares
November 13, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
November 12, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
November 11, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ARGX
ZLAB
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
October 29, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
October 24, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Participation in November and December Investor Conferences
October 18, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
October 17, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
October 16, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
October 09, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
September 17, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
August 27, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Participation in September Investor Conferences
August 22, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
August 06, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
July 16, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ARGX
ZLAB
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
July 15, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
July 10, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
June 11, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 22, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
May 20, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Participation in May and June Investor Conferences
May 16, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
May 14, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
May 12, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
May 08, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
April 15, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
April 11, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
April 02, 2024
From
Zai Lab Limited
Via
Business Wire
Tickers
ZLAB
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.